Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical’s stock (NASDAQ: ISRG) has outperformed with over a 50% gain since the recent lows of March 23, compared to the broader S&P 500, which gained 34%. Looking at other medical device companies, Abbott and Boston Scientific gained 40% each, and Medtronic rose 31%.

Is There More Upside For Intuitive Surgical’s Stock After A 50% Rebound?

Intuitive Surgical: The Growth Leader In Surgical Robotics

Intuitive Surgical sees its Relative Strength Rating enter the key 80-plus level.
The post Intuitive Surgical Stock Pushes Higher, Earning Rating Upgrade As It Strives For Pre-Covid-19 Crash High appeared first on Investor's Business Daily.

Intuitive Surgical Stock Pushes Higher, Earning Rating Upgrade As It Strives For Pre-Covid-19 Crash High

Amazon

NextEra Energy

Block

U.S. Bancorp

These top-tier growth and income stocks can help forge your financial independence.

5 Top Stocks to Secure Your Financial Freedom

ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?

Is ISRG Stock A Buy After Coronavirus Slammed Quarterly Growth?

Alexion Pharma

Livongo Health Inc

These healthcare stocks are already dominant, and it should remain that way for a long time to come.

3 Healthcare Stocks With Sustainable Competitive Advantages

Brookfield Infrastructure Partners L.P.

Disney

These top picks have seen shares slump in 2020 but should be long-term outperformers.

3 Bargain Stocks  You Can Buy Right Now

Wells Fargo

Long-term-minded investors should be rolling in the dough with these sound companies.

Investing $1,000 in These 3 Stocks Would Be a Smart Move

Palo Alto Networks

Married couples filing jointly who receive a maximum Economic Impact Payment would be smart to buy into these great companies.

3 Top Stocks to Buy With Your $2,400 Stimulus Payout

The company is facing headwinds, and it's performing slightly worse than the market. Is it worth the price?

Why Investors Are Paying a Premium For Intuitive Surgical

Activision Blizzard

Delta Air Lines

Ford Motor Company

Nordstrom

Kohl's

Macy's

Marriott

Microsoft

NIKE

Occidental Petroleum

Regeneron Pharmaceuticals

Visa

Nothing feeds fear in the stock market like uncertainty, and nothing spreads fear and uncertainty like a global pandemic.

6 Stocks to Buy and Hold (And 6 Picks to Avoid)

These stocks do one thing very well... outperform.

Have $3,000? Invest It Into These Surefire Winners

Despite a 16% decline in Intuitive Surgical’s (NASDAQ: ISRG) stock since the beginning of the year, at the current price of around $500, we believe Intuitive Surgical’s stock hasn’t bottomed out yet. Why is that?

Can Intuitive Surgical Fall Below $400?

A Relative Strength Rating upgrade for Intuitive Surgical shows improving technical performance. Will it continue?

Robotic Surgery Systems Maker Intuitive Surgical's Stock Earns Key Rating Upgrade

SUNNYVALE, Calif., April  28, 2020  (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today provided an update on its efforts to support customers, communities, and its employees during the COVID-19 pandemic.

Intuitive Provides Update on Supporting Customers, Communities & Employees during COVID-19

SUNNYVALE, Calif., April  27, 2020  (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the election of Joseph C. Beery to its board of directors, effective April 23, 2020.

Intuitive Appoints Joseph C. Beery to its Board of Directors

Intuitive Surgical: A Fairly Valued Medtech Benefiting From A Steadily Growing Robotic Surgery Market

Alphabet

These stocks should be sitting pretty when the COVID-19 pandemic is in the rearview mirror.

3 Great Stocks You Can Buy to Profit in a Post-Coronavirus World

Adobe

These financial rock stars are built to last.

3 Stocks You Can Set and Forget

Mastercard

Exxon Mobil

A plunging stock market is your opportunity to buy great businesses at a discount.

5 Smart Stocks to Buy During a Stock Market Crash

“Elective” surgeries can only be delayed for so long.

Intuitive Surgical's Coronavirus Slump Is Likely to Be Brief

The company's shares gained about half a percentage point following its quarterly update.

Intuitive Surgical Posts Solid Results, but the Future Is Hazy

Medtronic

Veeva Systems

These industry leaders will emerge from the coronavirus pandemic stronger than ever.

3 Best Healthcare Stocks to Buy for the Next Decade

Intuitive Surgical (ISRG) first-quarter results benefit from strong growth across all businesses and higher revenues.

Intuitive Surgical (ISRG) Q1 Earnings Beat Estimates, Up Y/Y

Intuitive Surgical, Inc (ISRG) CEO Gary Guthart on Q1 2020 Results - Earnings Call Transcript

News for Intuitive Surgical Stock (ISRG)